Kane Biotech Announces FDA 510(k) Clearance for its coactiv+ Antimicrobial Wound Gel - Seite 2

About coactiv+

coactiv+ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1^st and 2^nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult populations. It is also indicated for management of minor skin scrapes, minor cuts, minor lacerations, minor burns (1^st degree burns) and abrasions for adult populations.

coactiv+ Antimicrobial Wound Gel is a white, odorless hydrogel that provides a moist wound environment conducive to wound healing. coactiv+ Antimicrobial Wound Gel can facilitate debridement through a moist wound environment.

About Kane Biotech

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (80 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.

For more information:
Marc Edwards			Ray Dupuis	Nicole Sendey
Chief Executive Officer			Chief Financial Officer	Investor Relations/PR
Kane Biotech Inc			Kane Biotech Inc	Kane Biotech Inc
[e-mail]			[e-mail]	[e-mail]

Notes to Editor/References:

1. Based on market research conducted on Kane’s behalf.

2. Sen, C. K. (2021, March 31). Human wound and its burden: Updated 2020 compendium of estimates. Human Wound and Its Burden: Updated 2020 Compendium of Estimates from https://www.liebertpub.com/doi/10.1089/wound.2021.0026